Best Linagliptin Dapagliflozin Metformin Tablets Supplier Manufacturer

• he page is titled “Best Linagliptin Dapagliflozin Metformin Tablets Supplier & Manufacturer”.

• It describes Burgeon Health Series as a leading supplier and manufacturer for this triple‑drug combination, offering third‑party manufacturing and PCD (Propaganda cum Distribution) franchise opportunities.

• According to them, reasons to choose their service include:

  • Custom (tailored) manufacturing according to brand specs.

  • Adherence to “ISO‑GMP international standards of quality,” ensuring safety and efficacy.

  • Production scalability — small to bulk orders.

  • Faster “time-to-market” vs. setting up in-house manufacturing.

• The page also outlines the benefits of the triple combination in managing type 2 diabetes (T2DM):

  • It claims the combination “works synergistically” for controlling blood sugar, improving insulin sensitivity, and overall glycemic control.

  • It lists general advantages: reduction of liver glucose production, enhanced insulin sensitivity, excretion of excess glucose via urine (due to the SGLT‑2 inhibitor effect), and improved long-term glycemic control with minimal weight gain.

• Under “Uses …” they note the tablets are “widely prescribed for managing type 2 diabetes in adults who require multiple therapies to control their blood sugar.”

• The page includes a “Precautions and Adverse Effects” section:

  • Advises patients to take tablets under doctor’s supervision.

  • Warns about potential kidney stress from dapagliflozin, and recommends regular monitoring.

  • Advises adequate hydration (since SGLT‑2 drugs can increase urine output).

  • Mentions possible side effects: mild gastrointestinal upset (nausea or diarrhoea), increased risk of urinary tract infections (UTIs), and — very rarely — hypoglycemia when combined with other glucose-lowering medicines

• It argues that a “reputable manufacturer” is important to assure quality, efficacy, timely delivery, and scalable production — essentially pitching itself as a reliable manufacturing partner.

• The page ends by summarizing that Burgeon Health Series is a “trusted” supplier/manufacturer, providing third‑party manufacturing and PCD‑franchise services, aimed at enabling business growth while delivering effective diabetes management solutions.

 Critical Context & What’s Missing / Need Caution

• While the page markets the triple-drug combo (linagliptin + dapagliflozin + metformin), it doesn’t provide any independent scientific evidence, clinical trial data, regulatory approval references or published studies to support safety or efficacy of that particular fixed-dose combination (FDC).

• According to a recent regulatory update: the relevant national regulatory authority in India — Central Drugs Standard Control Organization (CDSCO) — recently rejected a proposed FDC containing a DPP‑4 inhibitor (linagliptin), a SGLT-2 inhibitor (empagliflozin in that case), and Metformin — noting insufficient evidence of benefit, lack of international approval, and lack of supporting published literature.

• That decision raises general caution about the use of triple or multi‑drug fixed combinations involving SGLT‑2 + DPP‑4 inhibitors + Metformin — especially without robust supporting evidence and regulatory backing.

• Independent sources of supply/ manufacturing for combinations like linagliptin + dapagliflozin + metformin remain limited: e.g., there is publicly known launch of such a combo in India by Theon Pharmaceuticals (linagliptin + dapagliflozin + metformin hydrochloride SR tablets) — reportedly the “first in India” as of 2024/2025.

• Absence of discussion of regulatory approvals (e.g. DCGI or CDSCO clearance), manufacturing licence number, batch‑testing data, quality certifications on the “Burgeon” page — which are usually essential for a safe/legitimate pharmaceutical supplier.

• There is also a broader warning from major regulators such as U.S. Food and Drug Administration (FDA) about products sold over internet claiming to treat diabetes — especially when ingredients are undisclosed or unverified. These may pose serious health risks.

✅ My Interpretation & What You Should Do (Given Your Background)

Because you mention having paralysis and presumably concerns about health:

• The claims on the “Burgeon Health Series” page seem promotional/business‑oriented, not evidence-based medical guidance. They lack credible scientific references or regulatory transparency that I would expect from a trustworthy pharmaceutical manufacturer or supplier.

• Given that triple‑drug FDCs (SGLT‑2 + DPP‑4 + Metformin) are controversial: even regulatory authorities have recently rejected some proposed formulations due to insufficient evidence.

• Using such a medicine — especially from a source lacking clear regulatory verification — in a complex medical situation (you have paralysis, may have other health concerns) could be risky.

Recommendation: Before considering such a medication (or sourcing from such a manufacturer), discuss with a qualified physician or endocrinologist. Ask for:

• Evidence of regulatory approval (e.g. licence number, DCGI/CDSCO registration),

• Clinical trial or published safety/efficacy data for that specific combination,

• Potential drug interactions and suitability given your overall health status.